Q2 ORAL CARE KIT WITH CHG- hydrogen peroxide and chlorhexidine gluconate kit

Q2 Oral Care Kit with CHG by

Drug Labeling and Warnings

Q2 Oral Care Kit with CHG by is a Prescription medication manufactured, distributed, or labeled by Halyard Health, Avent, Elba, Hi Tech Pharmacal. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

SPL UNCLASSIFIED SECTION

Oral Debriding Agent

Drug Facts

Active Ingredient

Hydrogen Peroxide 1.5%

Purpose

Oral Debriding Agent

Uses

• Aids in the removal of phlegm, mucus, or other secretions in the temporary relief of discomfort due to occasional sore throat and sore mouth.

Warnings

Stop use and ask a doctor if:

• Swelling, rash, or fever develop.
• Severe or persistent sore throat or sore throat accompanied by high fever, headache, nausea, and vomiting occurs.

• Do not use more than 2 days or administer to children under 3 years of age unless directed by a physician.

Keep out of reach of children under 3 years of age.

Directions

• Topical dosage for adults and children 3 years of age and older is a rinse used no more than 4 times daily. For children under 3 years of age, there is no recommended dosage except under the advice and supervision of a dentist or doctor.
• Use only under health care practitioners supervision.

Other Information

• Store at room temperature.

Inactive Ingredients

Purified Water, Glycerin, Flavor, Sodium Saccharin

Questions or Comments?

1-844-425-9273

 

SPL UNCLASSIFIED SECTION

CHLORHEXIDINE GLUCONATE ORAL RINSE, 0.12%

Rx Only

DESCRIPTION

Chlorhexidine Gluconate Oral Rinse, 0.12% is an oral rinse containing 0.12% chlorhexidine gluconate (1, 1'-hexamethylene bis[5-(p-chlorophenyl) biguanide] di-D-gluconate) in a base containing 11.6% v/v alcohol, FD&C Blue No. 1, glycerin, PEG-40 sorbitan diisostearate, peppermint flavor, sodium saccharin, and purified water. Chlorhexidine Gluconate Oral Rinse is a near-neutral solution (pH range 5-7). Chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid. Its structural formula is: C22H30Cl2N102C6H12O7 MW = 897.8

CLINICAL PHARMACOLOGY

Chlorhexidine Gluconate Oral Rinse, 0.12% provides antimicrobial activity during oral rinsing. The clinical significance of 0.12% chlorhexidine gluconate oral rinse's anti-microbial activities is not clear. Microbiological sampling of plaque has shown a general reduction of counts of certain assayed bacteria, both aerobic and anaerobic, ranging from 54-97% through six months use. Use of chlorhexidine gluconate oral rinse in a six month clinical study did not result in any significant changes in bacterial resistance, overgrowth of potentially opportunistic organisms or other adverse changes in the oral microbial ecosystem. Three months after chlorhexidine gluconate use was discontinued, the number of bacteria in plaque had returned to baseline levels and resistance of plaque bacteria to chlorhexidine gluconate was equal to that at baseline.

PHARMACOKINETICS

Pharmacokinetic studies with a 0.12% chlorhexidine gluconate oral rinse indicate approximately 30% of the active ingredient, chlorhexidine gluconate, is retained in the oral cavity following rinsing. This retained drug is slowly released into the oral fluids. Studies conducted on human subjects and animals demonstrate chlorhexidine gluconate is poorly absorbed from the gastrointestinal tract. The mean plasma level of chlorhexidine gluconate reached a peak of 0.206 µg/g in humans 30 minutes after they ingested a 300-mg dose of the drug. Detectable levels of chlorhexidine gluconate were not present in the plasma of these subjects 12 hours after the compound was administered. Excretion of chlorhexidine gluconate occurred primarily through the feces (~90%). Less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.

INDICATIONS AND USAGE

16 oz. Chlorhexidine Gluconate Oral Rinse, 0.12% - Chlorhexidine Gluconate Oral Rinse, 0.12% is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine Gluconate Oral Rinse, 0.12% has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.

CONTRAINDICATIONS

Chlorhexidine Gluconate Oral Rinse, 0.12% should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

WARNINGS

The effect of Chlorhexidine Gluconate Oral Rinse, 0.12% on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in users of chlorhexidine gluconate oral rinse compared with control users. It is not known if chlorhexicine gluconate use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Hypersensitivity and generalized allergic reactions have occurred. See CONTRAINDICATIONS.

PRECAUTIONS

General

1. For patients having coexisting gingivitis and periodontitis, the presence or absence of gingival inflammation following treatment with Chlorhexidine Gluconate Oral Rinse, 0.12% should not be used as a major indicator of underlying periodontitis.
2. Chlorhexidine Gluconate Oral Rinse, 0.12% can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsum of the tongue. Not all patients will experience a visually significant increase in toothstaining. In clinical testing, 56% of chlorhexidine gluconate oral rinse users exhibited a measurable increase in facial anterior stain, compared to 35% of control users after six months; 15% of chlorhexidine gluconate users developed what was judged to be heavy stain, compared to 1% of control users after six months. Stain will be more pronounced in patients who have heavier accumulations of unremoved plaque. Stain resulting from use of Chlorhexidine Gluconate Oral Rinse, 0.12% does not adversely affect health of the gingivae or other oral tissues. Stain can be removed from most tooth surfaces by conventional professional prophylactic techniques. Additional time may be required to complete the prophylaxis. Discretion should be used when prescribing to patients with anterior facial restorations with rough surfaces or margins. If natural stain cannot be removed from these surfaces by a dental prophylaxis, patients should be excluded from Chlorhexidine Gluconate Oral Rinse, 0.12% treatment if permanent discoloration is unacceptable. Stain in these areas may be difficult to remove by dental prophylaxis and on rare occasions may necessitate replacement of these restorations.
3. Some patients may experience an alteration in taste perception while undergoing treatment with chlorhexidine gluconate oral rinse. Rare instances of permanent taste alteration following chlorhexidine gluconate oral rinse have been reported via post-marketing product surveillance.

Pregnancy

Teratogenic Effects

Pregnancy Category B

Reproduction studies have been performed in rats and rabbits at chlorhexidine gluconate doses up to 300 mg/kg/day and 40 mg/kg/day, respectively, and have not revealed evidence of harm to fetus. However, adequate and well-controlled studies in pregnant women have not been done. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Chlorhexidine Gluconate Oral Rinse, 0.12% is administered to nursing women.

In parturition and lactation studies with rats, no evidence of impaired parturition or of toxic effects to suckling pups was observed when chlorhexidine gluconate was administered to dams at doses that were over 100 times greater than that which would result from a person's ingesting 30 ml (2 capfuls) of chlorhexidine gluconate oral rinse, 0.12% per day.

Pediatric Use

Clinical effectiveness and safety of Chlorhexidine Gluconate Oral Rinse, 0.12% have not been established in children under the age of 18

Carcinogenesis, Mutagenesis, and Impairment of Fertility

In a drinking water study in rats, carcinogenic effects were not observed at doses up to 38 mg/kg/day. Mutagenic effects were not observed in two mammalian in vivo mutagenesis studies with chlorhexidine gluconate. The highest doses of chlorhexidine used in a mouse dominant-lethal assay and a hamster cytogenetics test were 1000 mg/kg/day and 250 mg/kg/day, respectively. No evidence of impaired fertility was observed in rats at doses up to 100 mg/kg/day.

ADVERSE REACTIONS

The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception, see WARNINGS and PRECAUTIONS. Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse.

The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1.0%. Among post marketing reports, the most frequently reported oral mucosal symptoms associated with chlorhexidine gluconate oral rinse, 0.12% are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia.

Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using chlorhexidine gluconate oral rinse, 0.12%.

There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadentis) reported in patients using chlorhexidine gluconate oral rinse.

To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Ingestion of 1 or 2 ounces of Chlorhexidine Gluconate Oral Rinse, 0.12% by a small child (~10 kg body weight) might result in gastric distress, including nausea, or signs of alcohol intoxication. Medical attention should be sought if more than 4 ounces of Chlorhexidine Gluconate Oral Rinse, 0.12% is ingested by a small child or if signs of alcohol intoxication develop.

DOSAGE AND ADMINISTRATION

Chlorhexidine Gluconate Oral Rinse, 0.12% therapy should be initiated directly following a dental prophylaxis. Patients using Chlorhexidine Gluconate Oral Rinse, 0.12% should be reevaluated and given a thorough prophylaxis at intervals no longer than six months.

Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after toothbrushing. Usual dosage is 1/2 fl oz (marked in cup) of undiluted Chlorhexidine Gluconate Oral Rinse, 0.12%. Patients should be instructed to not rinse with water or other mouthwashes, brush teeth or eat immediately after using Chlorhexidine Gluconate Oral Rinse, 0.12%. Chlorhexidine Gluconate Oral Rinse, 0.12% is not intended for ingestion and should be expectorated after rinsing.

HOW SUPPLIED

Chlorhexidine Gluconate Oral Rinse, 0.12% is a blue, peppermint flavored liquid in:

A 16 fl oz (473 mL) amber plastic bottle with a child-resistant closure and dosage cup for consumer use, and in 15 mL unit dose cups.

It should be dispensed in original container or in amber glass.

Store above freezing 0°C (32°F).

SPL UNCLASSIFIED SECTION

Rx only

Manufactured by:
Hi-Tech
Pharmacal Co., Inc.
Amityville, NY 11701

Rev. 720:00 7/10
MG# 11387

PRINCIPAL DISPLAY PANEL - Kit Carton

HALYARD*

24-HOUR
ORAL CARE KIT
with BALLARD* Technology

Use
with
CHG
▼
CHG

with
H2O2

q2

1
HALYARD*
Prep
Pack

2
HALYARD*
Toothbrush
Packs

4
HALYARD*
Suction Swab
Packs with H2O2

6
HALYARD*
Suction Swab Packs
with Alcohol-Free Mouthwash

2
HALYARD*
Suction Catheter
Packs

INGREDIENTS AND APPEARANCE

Q2 ORAL CARE KIT WITH CHG 
hydrogen peroxide and chlorhexidine gluconate kit

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC: 69697-982

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 69697-982-01	1 in 1 CARTON

Quantity of Parts
Part #	Package Quantity	Total Product Quantity
Part 1	4 CUP, UNIT-DOSE	56 mL
Part 2	6 CUP, UNIT-DOSE	84 mL
Part 3	10 TUBE	100 g
Part 4	10 CUP, UNIT-DOSE	150 mL

Part 1 of 4

HYDROGEN PEROXIDE 
hydrogen peroxide mouthwash

Product Information
Item Code (Source)	NDC: 69697-991
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
Hydrogen peroxide (UNII: BBX060AN9V) (Hydrogen peroxide - UNII:BBX060AN9V)	Hydrogen peroxide	0.015 mg  in 1 mL

Inactive Ingredients
Ingredient Name	Strength
Water (UNII: 059QF0KO0R)
Glycerin (UNII: PDC6A3C0OX)
Mint (UNII: FV98Z8GITP)
Saccharin Sodium Dihydrate (UNII: SB8ZUX40TY)

Product Characteristics
Color		Score
Shape		Size
Flavor	MINT	Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 69697-991-01	14 mL in 1 CUP, UNIT-DOSE; Type 1: Convenience Kit of Co-Package

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC MONOGRAPH NOT FINAL	part356	08/26/2008

Part 2 of 4

ALCOHOL FREE MOUTHWASH 
mouthwashes and breath fresheners (liquids and sprays) mouthwash

Product Information
Route of Administration	ORAL

Other Ingredients
Ingredient Kind	Ingredient Name	Quantity
INGR	water (UNII: 059QF0KO0R)
INGR	Benzoic Acid (UNII: 8SKN0B0MIM)
INGR	Saccharin Sodium Dihydrate (UNII: SB8ZUX40TY)
INGR	Sodium Benzoate (UNII: OJ245FE5EU)
INGR	Glycerin (UNII: PDC6A3C0OX)
INGR	Cetylpyridinium Chloride (UNII: D9OM4SK49P)
INGR	D&C Green no. 5 (UNII: 8J6RDU8L9X)
INGR	Sorbitol (UNII: 506T60A25R)
INGR	Mint (UNII: FV98Z8GITP)

Product Characteristics
Color		Score
Shape		Size
Flavor	MINT	Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1		14 mL in 1 CUP, UNIT-DOSE; Type 1: Convenience Kit of Co-Package

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Cosmetic		03/13/2008

Part 3 of 4

MOUTH MOISTURIZER 
other oral hygiene products unassigned

Product Information
Route of Administration	ORAL

Other Ingredients
Ingredient Kind	Ingredient Name	Quantity
INGR	water (UNII: 059QF0KO0R)
INGR	Xylitol (UNII: VCQ006KQ1E)
INGR	Sodium Benzoate (UNII: OJ245FE5EU)
INGR	Aloe Vera Leaf (UNII: ZY81Z83H0X)
INGR	Propylene Glycol (UNII: 6DC9Q167V3)
INGR	Potassium Sorbate (UNII: 1VPU26JZZ4)
INGR	Sorbitol (UNII: 506T60A25R)
INGR	Hydroxypropyl Cellulose (Type H) (UNII: RFW2ET671P)
INGR	Dimethicone (UNII: 92RU3N3Y1O)
INGR	Potassium Chloride (UNII: 660YQ98I10)

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1		10 g in 1 TUBE; Type 1: Convenience Kit of Co-Package

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Cosmetic		06/25/2008

Part 4 of 4

CHLORHEXIDINE GLUCONATE 
chlorhexidine gluconate rinse

Product Information
Item Code (Source)	NDC: 50383-720
Route of Administration	ORAL

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
Chlorhexidine Gluconate (UNII: MOR84MUD8E) (Chlorhexidine - UNII:R4KO0DY52L)	Chlorhexidine Gluconate	1.2 mg  in 1 mL

Inactive Ingredients
Ingredient Name	Strength
Alcohol (UNII: 3K9958V90M)
FD&C Blue no. 1 (UNII: H3R47K3TBD)
Glycerin (UNII: PDC6A3C0OX)
PEG-40 sorbitan diisostearate (UNII: JL4CCU7I1G)
Mint (UNII: FV98Z8GITP)
Saccharin Sodium Dihydrate (UNII: SB8ZUX40TY)
Water (UNII: 059QF0KO0R)

Product Characteristics
Color	BLUE	Score
Shape		Size
Flavor	PEPPERMINT	Imprint Code
Contains

Packaging
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC: 50383-720-15	10 in 1 TRAY
1		15 mL in 1 CUP, UNIT-DOSE; Type 1: Convenience Kit of Co-Package

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA074356	05/07/1996

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA074356	05/07/1996

Labeler - Halyard Health (079617666)

Establishment
Name	Address	ID/FEI	Business Operations
Avent		049316284	LABEL(69697-982) , MANUFACTURE(69697-982) , PACK(69697-982)

Establishment
Name	Address	ID/FEI	Business Operations
Elba		108428483	MANUFACTURE(69697-982)

Establishment
Name	Address	ID/FEI	Business Operations
Hi Tech Pharmacal		101196749	MANUFACTURE(69697-982)